Category: Accesswire

Tax Identity Theft on the Rise in 2025 – Clear Start Tax Urges Victims to Act Quickly to Limit IRS Damage

IRVINE, CA / ACCESS Newswire / June 25, 2025 / Even after the April 15 deadline, tax identity theft continues to spike in 2025. Clear Start Tax is warning taxpayers to stay alert for one of the most damaging forms of IRS fraud: discovering that someone else has already filed a return in your name. Left unaddressed, this growing issue can delay refunds, trigger audits, and cause years of financial headaches.

The IRS has already flagged a surge in suspicious early-season filings, often from criminals using stolen personal information to claim refunds fraudulently. Unfortunately, many victims don’t realize what has happened until they attempt to file and receive a rejection stating that their return has “already been filed.”

“It’s one of the most stressful tax situations a person can face,” said the Head of Client Solutions at Clear Start Tax. “You’re locked out of your own account, refunds are frozen, and the IRS clock doesn’t stop. But with the right steps, you can regain control.”

Signs Someone Else Filed Using Your Information

If someone uses your Social Security Number to file a tax return, the IRS may process the fraudulent return before you even realize it. Clear Start Tax says to watch for the following red flags:

• Your e-filed return is rejected because a return was already submitted using your SSN.

• The IRS says a refund was issued, but you haven’t filed, and didn’t receive the funds.

• The IRS sends a notice about a suspicious return, new account activity, or a balance due from an unfamiliar filing.

• Your IRS account shows filings or income you don’t recognize.

Tax identity theft can leave you responsible for balances or penalties you didn’t cause. To protect yourself and explore your options under the IRS Fresh Start Program, answer a few quick questions and take the first step toward resolution.

What To Do If You Suspect Tax Identity Theft

The IRS has a formal process for victims of identity theft, but fast action is critical. Clear Start Tax outlines the steps you should take right away if you think someone has filed a return using your Social Security number:

1. File IRS Form 14039 (Identity Theft Affidavit) immediately to alert the IRS of suspected fraud.

2. Respond to any IRS notices – do not ignore them, even if they reference a return you didn’t file.

3. Request a copy of the fraudulent return by submitting Form 4506-F for further investigation.

4. File your real return by paper (not e-file) and include all required identity verification documents.

Clear Start Tax adds that many victims fail to respond quickly enough, which can delay the resolution process or lead to enforced balances for tax debt they don’t actually owe.

How Clear Start Tax Helps Identity Theft Victims

Tax identity theft cases can be difficult to navigate without expert help, especially when IRS systems continue to flag your account. Clear Start Tax supports affected clients by handling the entire response process:

• Managing all IRS correspondence

• Filing Forms 14039 and 4506-F

• Correcting account records and securing account transcripts

• Rebuilding compliance and applying for appropriate taxpayer protections

“We’ve helped clients who were wrongly pursued for years because of identity theft,” said the Head of Client Solutions at Clear Start Tax. “The key is fast documentation, clean records, and expert follow-through – especially when the IRS system flags your account.”

Don’t Wait for the IRS to Sort It Out

Identity theft cases can take months or even years to fully resolve, especially when there’s overlap with back taxes, unfiled returns, or penalties. Victims who act quickly, keep clear documentation, and work with experienced professionals are more likely to avoid long-term damage.

About Clear Start Tax

Clear Start Tax is a full-service tax liability resolution firm that serves taxpayers throughout the United States. The company specializes in assisting individuals and businesses with a wide range of IRS and state tax issues, including back taxes, wage garnishment relief, IRS appeals, and offers in compromise. Clear Start Tax helps taxpayers apply for the IRS Fresh Start Program, providing expert guidance in tax resolution. Fully accredited and A+ rated by the Better Business Bureau, the firm’s unique approach and commitment to long-term client success distinguish it as a leader in the tax resolution industry.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/

(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
seo@clearstarttax.com
(949) 535-1627

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / June 25, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced new in vitro preclinical data generated by Eurofins supporting the therapeutic potential of SKNY-1, a next-generation oral drug candidate being developed by SKNY Pharmaceuticals, Inc. (“SKNY”). MIRA has signed a definitive agreement to acquire SKNY, and the proposed transaction remains subject to regulatory review and shareholder approval.

SKNY-1 is being developed to help individuals lose weight and quit smoking by targeting key biological pathways involved in appetite, addiction, and reward-without triggering the central nervous system (CNS) side effects that have historically limited cannabinoid-based therapies.

“We believe SKNY-1 could be a first-in-class oral therapy for two of the largest and most underserved markets: obesity and nicotine addiction,” said Erez Aminov, CEO of MIRA. “What makes this drug candidate so exciting is its precision-it’s engineered to avoid the psychiatric side effects that doomed earlier drugs in this class, while offering a safe, convenient, once-daily oral option.”

Designed for Selectivity and Safety
Previous CB1-targeting drugs, such as rimonabant (Acomplia®, Sanofi), showed weight loss and metabolic results but were ultimately withdrawn from the market due to serious psychiatric side effects, including depression and suicidal ideation.¹ These effects stemmed from non-selective inhibition of CB1 signaling in the brain.

In contrast, in vitro studies conducted by Eurofins demonstrated that SKNY-1 acts as a biased CB1 modulator-selectively blocking the β-arrestin signaling pathway, which is associated with cravings and compulsive behavior, while preserving G-protein signaling, which is important for emotional and cognitive stability. This selective mechanism is designed to reduce cravings and body weight without disrupting mood.

A Dual Receptor Strategy-Engaging CB2 for Metabolic Support
In addition to CB1 modulation, SKNY-1 also interacts with the CB2 receptor, which plays a critical role in metabolic regulation and inflammation. Eurofins’ in vitro data show that SKNY-1 behaves as a partial CB2 agonist, potentially enhancing fat metabolism, reducing peripheral inflammation and improving insulin sensitivity. This dose-dependent flexibility distinguishes SKNY-1 from earlier CB1-only drugs and may enable a broader therapeutic impact on obesity-related pathways.

“SKNY-1 combines modern pharmacology with real-world practicality,” said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. “By precisely modulating CB1 and CB2 and supporting dopamine stability, it targets obesity and addiction through multiple, complementary mechanisms while potentially avoiding cannabinoid-related psychiatric side-effects.”

Dopamine Stability Without Stimulant Risk
SKNY-1 also mildly inhibits the MAO-B enzyme, helping regulate dopamine, a neurotransmitter involved in motivation, focus, and reward. Unlike older monoamine inhibitors, SKNY-1 does not inhibit MAO-A, reducing the risk of serotonin-related side effects. Importantly, the compound demonstrated no or minimal antagonist binding to dopamine receptors (D1, D2, D3), further supporting its favorable CNS safety profile.

A Differentiated Alternative to Injectables
While injectable GLP-1 drugs have gained market attention, they are often associated with gastrointestinal side effects and muscle loss. SKNY-1 is being developed as an oral therapy with a profile and expected mechanism that may help preserve muscle mass and improve patient adherence by avoiding injections.

Market Outlook and Strategic Fit
Obesity and smoking remain two of the world’s leading causes of preventable death. The global obesity drug market is projected to surpass $150 billion in value by 2030, and the U.S. smoking cessation market is forecast to grow from $28 billion in 2024 to over $50 billion by decade’s end.

Pending the completion of the proposed acquisition, MIRA believes SKNY-1 could become a cornerstone asset within its pipeline, offering a next-generation solution to two major health challenges. The Company is currently finalizing animal data related to weight loss and nicotine addiction, which will further support its development strategy and future regulatory filings.

MIRA has submitted the required regulatory filings to the U.S. Securities and Exchange Commission (SEC) in connection with the proposed acquisition of SKNY. A shareholder vote will follow in accordance with SEC regulations.

For more information, please visit: www.mirapharmaceuticals.com

About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as anxiety, cognitive decline, neuropathic pain, obesity, and addiction.

Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA’s management related thereto contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA’s current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA’s control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA’s potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA’s programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and MIRA’s website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Footnote:
¹ European Medicines Agency. “Acomplia Suspended as Risks Outweigh Benefits.” October 23, 2008.

CONTACT:
Helga Moya
info@mirapharma.com
(786) 432-9792

SOURCE: MIRA Pharmaceuticals

View the original press release on ACCESS Newswire

TAMPA, FL / ACCESS Newswire / June 25, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare technology company focused on building the future of prescription access and distribution, today announced significant Q2 2025 operational results-adding 116 new pharmaceutical manufacturer partnerships, over 12,400 new products (NDCs), and 275+ pharmacies to its national platform.

This expansion reflects Wellgistics’ accelerating momentum in creating a modern drug ecosystem-one that aims to connect manufacturers directly to pharmacies, providers, employers, and patients through a fully integrated, AI-powered infrastructure designed to streamline fulfillment, reduce costs, and bypass legacy bottlenecks.

“We’re in hyper structural transformation mode,” said Brian Norton, CEO of Wellgistics Health. “Pharma companies are signaling a shift. They want partners who can deliver speed, visibility, and direct access-not more layers of complexity. Every new manufacturer, every new product, and every new pharmacy is helping us rewire how prescriptions move in this country. We’re laying the foundation for real-time, patient-first drug access at national scale.”

As Wellgistics continues to advance toward direct-to-patient care programs, the company intends to leverage its expanding distribution, fulfillment, and pharmacy network to support new models of care-aligning pharmaceutical manufacturers with a streamlined path to market while offering patients faster, more transparent prescription access.

The Wellgistics platform spans the full prescription journey-from wholesale distribution and digital Rx routing to pharmacy dispensing and Hub Services including eligibility, prior authorization, adherence tracking, and patient engagement. With thousands of pharmacies on board and manufacturer demand accelerating, Wellgistics seeks to be a vital infrastructure partner for reshaping prescription drug delivery in the U.S.

About Wellgistics Health

Wellgistics Health (NASDAQ:WGRX) is a healthcare technology company built for the $500B prescription drug market. Our AI-powered, vertically integrated platform connects pharmaceutical manufacturers directly to providers, pharmacies, employers, and patients-managing the full journey from maker to taker. From distribution and digital routing to pharmacy fulfillment and Hub Services, Wellgistics is delivering the infrastructure to power a faster, smarter, and more transparent future in prescription access.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, Wellgistics Health’s statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from Wellgistics Health’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other risks detailed in our reports and statements filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health’s filings with the SEC, which are available for review at www.sec.gov.

For more information, please contact:

Media Contact: media@wellgisticshealth.com
Investor Relations: investors@wellgisticshealth.com

Investor Relations Contact:

Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, NY 10036
Office: (646) 893-5835
Email: info@skylineccg.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

TORONTO, ON / ACCESS Newswire / June 25, 2025 / Electrovaya Inc. (“Electrovaya” or the “Company”) (NASDAQ:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today announced that Dr. Raj DasGupta, Electrovaya’s CEO will be participating at the Roth 15th Annual-London Conference, held at the Four Seasons Park Lane in London, UK.

The Company’s participation underscores Electrovaya’s ongoing commitment to active engagement with the global financial community. During the conference, CEO, Raj DasGupta will take part in one-on-one and small group meetings with leading European institutional investors to discuss the Company’s strategic initiatives, technology roadmap, and long-term growth outlook.

Event: ROTH – 15th Annual – London Conference
Date: June 25-26, 2025
Location: Four Seasons Park Lane, London, UK
Format: 1×1 small group meetings – by invitation only

For more information on the ROTH – 15th Annual – London, UK Conference, or to schedule a one-on-one meeting with Electrovaya’s management, please contact your ROTH representative.

Investor and Media Contact:
Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
905-855-4618 / jroy@electrovaya.com

About Electrovaya Inc.
Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries and battery systems for energy storage and heavy duty electric vehicles based on its Infinity Battery Technology Platform. This technology offers enhanced safety and industry leading battery longevity. The Company is also developing next generation solid state battery technology at its Labs division. Headquartered in Ontario, Canada, Electrovaya has two operating sites in Canada and has acquired a 52-acre site with a 135,000 square foot manufacturing facility in New York state for its planned gigafactory. To learn more about Electrovaya, please explore www.electrovaya.com.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

Advancement of long lead work programs to support ML Application

HIGHLIGHTS

• Recent Tunkillia OSS confirms large-scale gold project yielding $2.7bn operating cash^[1]

• Barton accelerating key long-lead PFS and Mining Lease Application programs

ADELAIDE, AUSTRALIA / ACCESS Newswire / June 24, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to announce the start of baseline water monitoring programs for its South Australian Tunkillia Gold Project (Tunkillia), following the recent publication of Tunkillia’s Optimised Scoping Study (OSS).

The Tunkillia OSS identified a compelling large-scale operation with (at an A$5,000/oz gold price): ¹

• average annual production: ~120koz gold and ~250koz silver

• operating free cashflow: A$2.7 billion

• Net Present Value (NPV _7.5% ): A$1.4 billion

• Internal Rate of Return (IRR): 73%

• Payback period: 0.8 years, and

• A ‘Starter’ pit producing ~206koz Au for A$825m operating free cash in the first 13 months

Barton recently announced a $3 million equity accretive placement priced at a ~4% premium to its last traded price, and a ~25% premium to its 20 trading day volume weighted average price (VWAP).^[2] The use of those funds is primarily to accelerate Reserve conversation upgrade drilling for Tunkillia’s ‘Starter Pit. ² Drilling is anticipated to commence during September 2025, and complete by December 2025.

The baseline water monitoring program is another key long-lead feasibility and approvals work program, with a minimum of two years’ worth of baseline water data required prior to start of mining and production. The new Tunkillia water monitoring program will allow Barton to compare new baseline data with historical baseline data collected during prior analyses of the Tunkillia Gold Project.

Commenting on the start of Tunkillia water monitoring, Barton MD Alexander Scanlon said:

“Tunkillia’s Optimised Scoping Study has confirmed a large-scale, competitive gold and silver operation with significant economies of scale offering strong financial and capital leverage to a rapidly evolving gold market.

“During the balance of calendar year 2025 we will focus on key long-lead feasibility and approvals programs for Tunkillia, with the objective to submit a Mining Lease Application prior to the end of calendar year 2026.

“In parallel, we will be completing our studies for ‘Stage 1′ operations leveraging our Central Gawler Mill, with the objective to transition to ‘producer’ status during 2026. This will enable us to generate free cash flows, and use these funds to advance and develop Tunkillia as our ‘Stage 2′ expansion project. This staged approach offers our shareholders a lower-cost, lower-risk and lower-dilution pathway to 150,000ozpa gold production.”

Authorised by the Managing Director of Barton Gold Holdings Limited.

For further information, please contact:

Alexander Scanlon Managing Director a.scanlon@bartongold.com.au +61 425 226 649

Jade Cook Company Secretary cosec@bartongold.com.au +61 8 9322 1587

SOURCE: Barton Gold Holdings Limited

View the original press release on ACCESS Newswire

Company’s CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing

SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or “the Company”), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of convertible promissory notes originally issued by the Company as part of the previously announced $3.448 million bridge financing that closed on March 31, 2025. Prior to the extension, five investors converted $0.866 million (including accrued interest) of the original bridge financing into equity in the Company.

“We’re very pleased with each of the participants in this bridge financing that agreed to the extension of the maturity date,” said Lisa Conte, Jaguar’s Founder and CEO. “Each of these investors is committed to helping provide the resources needed to support Jaguar’s goal of forging corporate partnerships to bring in non-dilutive funding for the Company’s three core development programs for crofelemer, our novel plant-based prescription medicine: our orphan disease intestinal failure program; our ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and our ongoing development program to expand access for Canalevia^® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea.”

To view the original terms of the bridge financing, as announced on March 26, 2025, please click here. To view the terms of the extension, please refer to the Form 8-K filed by the Company today, June 24, 2025, which can be viewed on the SEC Filings page of Jaguar’s website. Click here to access the SEC Filings page of Jaguar’s website.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo’s crofelemer is FDA-approved under the brand name Mytesi^® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s goal of forging corporate partnerships to bring in non-dilutive funding for the Company’s three core development programs for crofelemer: the Company’s orphan disease intestinal failure program; the Company’s ongoing efforts to make crofelemer available for treatment of CTD in patients with metastatic breast cancer receiving selected targeted therapies; and the Company’s ongoing development program to expand access for Canalevia in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea.In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

hello@jaguar.health

Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

SAN BERNARDINO, CA / ACCESS Newswire / June 24, 2025 / Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF), a leading Australian mining and exploration company, today announced that its Managing Director, Stephen Baghdadi, has invested over $1.06 million in the company by exercising 53,000,208 share options. This significant capital injection underscores Baghdadi’s confidence in Dateline’s strategic direction and its flagship Colosseum Gold and Rare Earth Elements (REE) Project in California.

Baghdadi’s investment increases his shareholding to 396,890,307 shares, representing 12.85% of the company, further aligning his interests with those of shareholders. The $1.06 million cash injection bolsters Dateline’s financial position, bringing total cash and option exercise commitments to nearly $9 million. “Exercising these options was an easy decision because I have great confidence in Dateline’s long-term future. Our project is a high-quality asset with tremendous upside. Increasing my stake in the Company is a long-term investment for me and it underscores my commitment to our long-term vision and growth, and it enhances the company finances by bringing the total cash at bank and option exercise commitments to almost $9,000,000,” said Baghdadi.

The funds will support ongoing exploration and development at the Colosseum Project, located in California’s Walker Lane Trend. A past-producing gold mine, Colosseum has a JORC-2012 compliant Mineral Resource estimate of 27.1 million tonnes at 1.26 g/t gold for 1.1 million ounces, as announced on June 6, 2024. Recent exploration has revealed promising REE mineralization, positioning Colosseum as a unique dual-commodity opportunity. On May 23, 2025, Dateline reported updated economics for the project, projecting an NPV6.5 of $550 million and an IRR of 61% at a gold price of $2,900 per ounce. The project’s proximity to the Mountain Pass Rare Earth mine, less than 10 kilometers away, enhances its potential in the growing critical minerals market.

Dateline’s Board of Directors welcomed Baghdadi’s investment as a strong endorsement of the company’s strategy. “Stephen’s commitment reinforces our confidence in the Colosseum Project’s ability to deliver long-term value for shareholders,” the Board stated. The capital will advance drill testing to assess the project’s REE potential and further unlock its gold resources.

About Dateline Resources Limited

Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF) is an Australian company focused on mining and exploration in North America. The Company owns 100% of the Colosseum Gold-REE Project in California.

The Colosseum Gold Mine is located in the Walker Lane Trend in East San Bernardino County, California. On 6 June 2024, the Company announced to the ASX that the Colosseum Gold mine has a JORC-2012 compliant Mineral Resource estimate of 27.1Mt @ 1.26g/t Au for 1.1Moz. Of the total Mineral Resource, 455koz @ 1.47/t Au (41%) are classified as Measured, 281koz @1.21g/t Au (26%) as Indicated and 364koz @ 1.10g/t Au (33%) as Inferred.

On 23 May 2025, Dateline announced that updated economics for the Colosseum Gold Project generated an NPV6.5 of US$550 million and an IRR of 61% using a gold price of US$2,900/oz.

The Colosseum is located less than 10km north of the Mountain Rare Earth mine. Planning has commenced on drill testing the REE potential at Colosseum.

Forward-Looking Statements

This announcement may contain “forward-looking statements” concerning Dateline Resources that are subject to risks and uncertainties. Generally, the words “will”, “may”, “should”, “continue”, “believes”, “expects”, “intends”, “anticipates” or similar expressions identify forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond Dateline Resources’ ability to control or estimate precisely, such as future market conditions, changes in regulatory environment and the behavior of other market participants. Dateline Resources cannot give any assurance that such forward-looking statements will prove to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements. Dateline Resources assumes no obligation and does not undertake any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except to the extent legally required.

Competent Person Statement

Sample preparation and any exploration information in this announcement is based upon work reviewed by Mr Greg Hall who is a Chartered Professional of the Australasian Institute of Mining and Metallurgy (CP-IMM). Mr Hall has sufficient experience that is relevant to the style of mineralization and type of deposit under consideration and to the activity which he is undertaking to quality as a Competent Person as defined in the 2012 Edition of the “Australasian Code for Reporting Exploration Results, Mineral Resources and Ore Reserves” (JORC Code). Mr Hall is a Non-Executive Director of Dateline Resources Limited and consents to the inclusion in the report of the matters based on this information in the form and context in which it appears.

Contact Information

Stephen Baghdadi
Managing Director
Dateline Resources Limited
+61 2 9375 2353
info@datelineresources.com.au
www.datelineresources.com.au

Andrew Rowell
White Noise Communications
+61 400 466 226
andrew@whitenoisecomms.com

Follow Dateline on X: @Dateline_DTR

Dateline Resources Limited
Level 29, 2 Chifley Square, Sydney, NSW 2000, Australia

This press release is authorized for release by the Board of Dateline Resources Limited. and Development

SOURCE: Dateline Resources Limited

View the original press release on ACCESS Newswire

DALLAS, TX / ACCESS Newswire / June 24, 2025 / E-commerce returns are broken: expensive for merchants, frustrating for consumers, and riddled with inefficiencies that no one owns. Today, Orchestro.AI, the leader in intelligent decision systems for logistics and supply chains, announces a strategic partnership with PackageHub Business Centers® (PBC), the largest multi-carrier retail shipping network in the U.S., to transform reverse logistics at scale.

Together, the companies are building a smarter, more profitable, and consumer-friendly returns infrastructure – blending AI-powered decision intelligence with over 4,600 retail drop-off points covering 77% of U.S. e-commerce consumers.

“We’re building a returns network that listens, learns, and acts – one that transforms the chaos of ecommerce returns into coordinated intelligence,” said Shekar Natarajan, CEO of Orchestro.AI. “What if your network could understand intent – not just scan a label – and instantly orchestrate the best path forward? That’s what Orchestro enables. We’re not just adding visibility; we’re giving the parcel network a mind of its own – turning fragmented returns into a system that feels alive, adaptive, and almost effortless. For merchants, this means protecting the hard-won customer relationship, recovering margin, and delivering an experience that’s as smart as the sale itself.”

Returns, Reimagined for Modern Ecommerce

PackageHub® operates the largest carrier-agnostic returns network in the U.S., with more than 1,200 active franchises and access to over 3,400 additional drop-off locations. This gives brands unprecedented reach – rivaling USPS, UPS, and FedEx – with greater flexibility, control, and cost efficiency.

For merchants, this means:

– Branded, Amazon-grade return experiences – without the CapEx

– Lower cost-to-serve through volume consolidation and smart routing

– Flexibility to use any carrier, serve any brand, and meet any customer at scale

This infrastructure also empowers regional carriers to compete nationally – capturing shared returns volume and enabling local service excellence with national density.

“Merchants spend a fortune acquiring a customer – and a single bad return experience can lose them for good,” said Greg Ojeda, Chief Product & Strategy Officer at PackageHub®. “That’s why we’re focused on turning returns from a churn risk into a loyalty driver. Orchestro gives us the intelligence layer to surface cost drivers, fight fraud, and deliver a smooth, branded experience at scale – exactly where our network thrives. As complexity grows inside stores, it’s critical that we protect the experience of both customers and employees. AI gives us the opportunity to reduce friction, automate the messy parts, and create a simpler, more rewarding retail environment for everyone involved.”

Scale of the Opportunity – and the Urgency

– Global ecommerce is projected to reach $6.9 trillion in 2025

– U.S. returns surpassed $890 billion in 2024, with ecommerce return rates over 17%

– More than 4 billion parcels are returned annually

– 60% of customers say that easy returns directly influence brand loyalty

Amazon has set the standard. Everyone else is racing to catch up – and many are bleeding margin trying.

Built for Margin, Loyalty, and Operational Edge

Orchestro.AI powers the intelligence layer that makes returns profitable at scale:

– Identifies hidden cost drivers across the reverse chain

– Detects and prevents fraud at the point of return

– Benchmarks and improves carrier and logistics partner performance

– Simulates return paths to optimize speed, cost, and convenience

Orchestro’s platform acts as the digital thread weaving together every step of the reverse journey – from return label creation to drop-off, routing, processing, and refund. This visibility allows brands to treat returns not as isolated transactions, but as end-to-end, data-rich events that inform inventory, pricing, and customer strategy.

All without disrupting existing workflows. The platform integrates seamlessly with a brand’s systems, carriers, and networks – making every return a data-driven opportunity, not a liability.

Simulate. Optimize. Orchestrate.

With Orchestro, brands can test carrier mix, regional strategies, and return models before deploying anything.

No more guesswork. No more rip-and-replace. Just orchestrated outcomes.

Strategic Highlights of the Partnership

– Returns Infrastructure at Scale – Over 4,600 drop-off locations and 77% e-commerce consumer coverage

– AI-Powered Optimization – Real-time insight, routing, and performance benchmarking

– Merchant-Centric Value – Reduced friction, recovered margin, smarter decisions

– Empowering Regional Carriers – Creating volume density to rival national incumbents

This isn’t just a tech partnership – it’s a new reverse logistics operating system. Together, Orchestro and PackageHub® are transforming one of ecommerce’s most overlooked and costly workflows into a high-leverage engine for loyalty, margin, and growth.

Contact

Interested brands can reach out at orchestro.ai/merchant to schedule a demo and explore partnership opportunities.

For media inquiries, please contact:
Shekar Natarajan
shekar@orchestro.ai
www.orchestro.ai

SOURCE: Orchestro.AI

View the original press release on ACCESS Newswire

AstroNova breached confidentiality, misrepresented private negotiations

Company demanded silence in exchange for no Board seats, no leadership change, and no path to value creation

Board continues to prioritize entrenchment over addressing shareholder concerns

FORT WORTH, TX / ACCESS Newswire / June 24, 2025 / Dear AstroNova Shareholders,

Yesterday evening, we thought we were participating in confidential negotiations with AstroNova aimed at reaching a collaborative solution to the ongoing proxy contest. This morning, AstroNova blindsided us with a news release publicly mischaracterizing those talks, thereby violating our agreement to keep our discussions private, and severely undermining the prospect of continued engagement. We already knew that AstroNova’s Board could not be trusted to deliver shareholder value; now we know they cannot be trusted to keep their word.

Breach of Trust

Sadly, we must also now share revealing details from an exchange that we were promised would remain private. Following a call with Mr. Warzala last week, we invited the company to propose a solution. Mr. Warzala sent an egregiously one-sided proposal that would entrench the current Board while silencing our ability to advocate for shareholders. The company proposed we sign a standstill agreement in exchange for:

1. No Board representation

2. Mr. Woods leaving the Board but remaining CEO

3. Askeladden attending a single Board meeting as an observer, with no voting rights

No sane professional investor would agree to such terms. They would restrict our ability to trade or speak freely, yet offer no corresponding ability to influence company decisions. The Board wanted our silence – not our input.

We told Mr. Warzala that we remained “happy to further discuss these topics” and “hope we can continue to have mutually beneficial dialogue,” but warned that “in the absence of a proposal that demonstrates the Board is committed to making […] substantial changes […] we’d much rather let shareholders decide who best represents their interests.” We also reiterated concrete steps that could safeguard shareholder interests, such as hiring a proven print industry executive or initiating a strategic alternatives process, yet Mr. Warzala showed no interest in exploring these ideas.

We intended to respond to Mr. Warzala’s latest email this morning. Instead, the company rushed to issue a news release – shutting off dialogue before we even had a chance to reply in detail. AstroNova abandoned any effort to engage when we provided candid feedback on the inadequacy of their initial proposal. Once again, the company seems more concerned with scoring PR points than with resolving shareholder concerns. This mirrors their prior conduct – demanding a call on an hour’s notice after months of ignoring us, then claiming we were reluctant to engage.

Other contradictions

The company’s press release is rife with other contradictions. The Board now claims it “shares many of Samir Patel’s concerns” and “began actively addressing many of these issues long before Samir commenced his proxy contest.” Yet in a letter two weeks ago, the company impugned my supposed “readily apparent […] lack of knowledge and understanding of AstroNova’s business.” Which version should shareholders believe – what the Board says today, or what they said two weeks ago?

Similarly, Mr. Warzala’s reference to a “takeover” is disingenuous. One of our publicly-stated priorities is to evaluate strategic alternatives to determine if substantially higher value could be achieved for all shareholders in private markets, yet the company has publicly dismissed this idea as unworthy of consideration. Finally, the Board claims it is “on track” to achieve a share price equivalent to the pre-pandemic peak – despite FY25 earnings results and FY26 earnings guidance that remain below FY24 levels.

After presiding over the MTEX disaster and the ensuing ~50% decline in shareholder value, the incumbent Board refuses to consider meaningful change – whether replacing the CEO, refreshing the Board, or exploring a sale. Their priorities are clear: maintaining control matters more than delivering results and restoring shareholder value.

We urge shareholders to vote to elect directors who truly care about rapidly maximizing shareholder value. If you need assistance in voting the GOLD proxy card, please contact InvestorCom at (877) 972-0090. If you would like to speak to me or any of our candidates, please don’t hesitate to contact me directly.

Sincerely,

Samir Patel
samir@askeladdencapital.com
(682) 553-8302

This filing, and future filings, will also be made available to shareholders after dissemination on EDGAR via our website: https://www.askeladdencapital.com/astronova/ These documents will also be available at no cost at www.sec.gov.

Samir Patel, Askeladden Capital Management LLC, Jeff Sands, Shawn Kravetz, Ryan Oviatt and Boyd Roberts (collectively the “Participants”) filed a definitive proxy statement and accompanying proxy card with the SEC on May 20, 2025, as amended on May 21, 2025, to be used in soliciting proxies in connection with the 2025 annual meeting of shareholders (the “Annual Meeting”) of AstroNova, Inc. (the “Company”). All shareholders of the Company are advised to read the Proxy Statement and other documents related to the solicitation of proxies, each in connection with the Annual Meeting, by the Participants, as they contain important information, including additional information related to the Participants, including a description of their direct or indirect interests by security holdings or otherwise. The Proxy Statement and an accompanying GOLD proxy card will be furnished to some or all of the Company’s stockholders and is, along with other relevant documents, available at no charge on the SEC website at http://www.sec.gov, or by contacting Samir Patel at 1452 Hughes Road, Suite 200 #582, Grapevine, TX, 76051.

SOURCE: Askeladden Capital Management LLC

View the original press release on ACCESS Newswire

Upstate Makes champions glass packaging as part of NSF Regional Innovation Engines proposal, spearheads development of a glass innovation and training hub

June 25 event to explore New York’s unique capabilities for next-gen, glass-based microelectronics – register here

ALBANY, NY / ACCESS Newswire / June 24, 2025 / FuzeHub, a leading nonprofit organization dedicated to assisting New York State manufacturers and technology companies, and a robust coalition of industry, academic and government partners have announced a strategic commitment through their collaborative Upstate Makes initiative to further explore the power of glass as an innovative advanced material to strengthen the U.S. microelectronics industry. This collaborative endeavor-a key element of FuzeHub’s proposal for the National Science Foundation’s Regional Innovation Engines Competition (NSF Engines)-aims to make Upstate New York a next-generation microelectronics manufacturing hub.

Last year, FuzeHub-led Upstate Makes was awarded $1 million through the Regional Innovation Engines Development Awards to cultivate new partnerships and nurture the state’s materials innovation ecosystem. Empire State Development’s Division of Science, Technology and Innovation (NYSTAR) furthered the impact of the NSF award with a $200,000 matching grant. Over the last year, Upstate Makes has expanded its project partners and gained significant validation from industry and academic leaders across New York State.

With Upstate Makes’ new strategic commitment and the region’s historic strength in glass production, Upstate New York is uniquely equipped to deliver new innovations in glass for microelectronics manufacturing-which will directly contribute to America’s manufacturing competitiveness and national defense.

“For more than a decade, we’ve seen glass discussed as a replacement material – and now, with leading-edge design, 6G wireless, and the demands of AI, it’s more important than ever to focus on investing in glass packaging in the semiconductor industry,” said FuzeHub Executive Director Elena Garuc. “Our region is uniquely positioned to make this vision of a world-renowned next-gen microelectronics manufacturing hub a reality, and we’re confident in our decision to focus on glass in our next steps for the Upstate Makes initiative.”

Last month, FuzeHub submitted its refined and expanded Upstate Makes proposal for the NSF Engines funding program. It was one of just 71 teams across the U.S. that was asked to submit a proposal-which could secure significant federal funding for the Upstate region.

Upstate Makes Partner Commitments, Vision for Glass Innovation Hub

The Upstate Makes coalition has grown to over 60 partners, ranging from materials science research labs and semiconductor industry leaders to entrepreneurial support centers and workforce development organizations. Spread across five metro areas in Upstate New York, this collection of partners will continue to pursue new innovations to strengthen U.S. microelectronics manufacturing and develop the workforce necessary for jobs in the industry. A list of contributing partners is available at upstatemakes.org/partners.

As part of its strategic initiatives, Upstate Makes is spearheading the development of a glass innovation and training hub in Upstate New York. This hub will offer a one-stop solution for industry partners, equipped with high-volume manufacturing (HVM) tools and infrastructure that support collaborative R&D and packaging innovation as well as workforce training. By fostering cross-sector partnerships and providing access to advanced manufacturing capabilities, the center aims to significantly reduce the time and cost of bringing new glass packaging technologies to market.

“Upstate New York is truly one of the only regions in the world with the capabilities and resources to achieve the vision outlined in the Upstate Makes proposal,” said Nicholas Fahrenkopf, NY CREATES Director and Technical Director of the Northeast Regional Defense Technology Hub (NORDTECH). NORDTECH is an Upstate Makes partner and a designated U.S. Microelectronics Commons hub. “With the potential to leverage federal investment through programs like NSF Engines, Upstate Makes can drive our region’s microelectronics industry forward, strengthen American manufacturing, and bolster our national security.”

Supporting National Security, Manufacturing Competitiveness

The Upstate Makes initiative is also advancing efforts to contribute to national defense. For example, the U.S. Department of Defense (DOD) has multiple critical applications for high-performance chips-ranging from fighter jet control systems to intelligence data analysis-where glass is an ideal solution to minimize power loss and improve semiconductor speed. The expertise in glass and microelectronics from Menlo Micro, Mosaic Microsystems and other industry partners can specifically foster this type of innovation.

Further, Griffiss Institute will create experiential learning programs for college and post-doctoral students that provide pathways to obtain security clearances and prepare them to contribute directly to Department of Defense applications. These programs reflect Griffiss Institute’s commitment to developing national security talent through nontraditional STEM education and real-world engagement. As a Partnership Intermediary Agreement (PIA) holder with the Air Force Research Laboratory Information Directorate (AFRL), Griffiss Institute also brings unique access to plan and support the transition of dual-use technologies, such as those in the emerging areas.

“Menlo Micro’s glass-based device, developed largely in Upstate New York, is addressing key RF, power and defense applications,” said Aric Shorey, VP of Glass Technologies and Government Affairs at Menlo Micro. “We are part of the high-performance computing and AI supply chain and addressing several applications important to National Defense. There is significant potential to expand through advanced glass packaging that can be accelerated through initiatives driven by Upstate Makes.”

“Domestically and sustainably, sourced glass has the potential to become an economic and technological runway for U.S.-based microsystems packaging in both commercial and defense applications,” added Jeff Fitzgerald, Technology Development Manager at FAST Labs™ BAE Systems, Inc.

June 25 Event: Global Leadership in Next-Gen, Glass-Based Microelectronics

Upstate Makes is leading an online event on Wednesday, June 25, to dive deeper into New York State’s unique capabilities and the collaborative efforts underway to establish global leadership in next-generation, glass-based microelectronics. To register, visit upstatemakes.org/glass-leadership-webinar/.

To learn more about how to get involved, visit upstatemakes.org.

About FuzeHub

FuzeHub is a not-for-profit organization that connects New York’s small to medium-sized manufacturing companies to the resources, programs, and expertise they need for technology commercialization, innovation, and business growth. Through our custom assessment, matching, and referral platform, we help companies navigate New York’s robust network of industry experts at Manufacturing Extension Partners centers, universities, economic development organizations, and other providers. FuzeHub is the statewide New York Manufacturing Extension Partnership Program (MEP) center, supported by Empire State Development’s Division of Science, Technology & Innovation. For more information on FuzeHub, visit www.fuzehub.com.

Not Export Controlled per ES-FL-050635-0044

Approved for Public Release, Distribution Unlimited

Media Contact

John Mackowiak
jmackowiak@martingroupmarketing.com
518.618.1175

SOURCE: FuzeHub

View the original press release on ACCESS Newswire